Colitis Reports with Breast Cancer Drugs Ibrance, Kisqali, and Verzenio Put Them on FDA’s Potential Risk List

FDA is evaluating a possible colitis risk with Ibrance, Kisqali, and Verzenio. A signal is not proof. Learn the symptoms to report to your care team.

Have A Referral?